首页> 美国卫生研究院文献>other >Intensity Modulated Proton Therapy with Advanced Planning Techniques in a Challenging Hepatocellular Carcinoma Patient
【2h】

Intensity Modulated Proton Therapy with Advanced Planning Techniques in a Challenging Hepatocellular Carcinoma Patient

机译:具有挑战性的肝细胞癌患者采用先进的计划技术进行强度调节质子治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The use of radiation therapy has been increasing over recent years for the treatment of hepatocellular carcinoma (HCC). Proton beam therapy (PBT) has emerged as a promising treatment option for HCC patients due to its dosimetric advantages of sparing more normal liver tissue from radiation at low to moderate doses compared to photon-based treatments while still delivering high doses of radiation to tumors. The PBT therapy may be particularly beneficial in high-risk HCC cirrhotic patients with large, bulky tumors and/or vascular invasion complicated by surrounding perfusion abnormalities. We present a case of a 62-year-old male with an unresectable 13 cm diffusely infiltrative HCC tumor with main portal vein invasion and elevated alpha-feta protein (AFP) of 37,200 that was intolerant of standard sorafenib treatment. He was treated with hypofractionated PBT to 67.5 GyE in 15 fractions using a novel combination of simultaneously integrated boost intensity modulated proton therapy (SIB-IMPT), breath hold technique, and functional liver imaging with technetium-99m [99mTc] sulfur colloid single-photon emission computed tomography (SPECT/CT) to assist in the differentiation of tumor and normal liver. He had a complete radiographic and biochemical response by AFP normalization by seven months post-treatment without evidence of radiation hepatotoxicity.
机译:近年来,放射疗法在肝细胞癌(HCC)治疗中的应用一直在增加。质子束治疗(PBT)已成为HCC患者的一种有前途的治疗选择,这是由于其剂量学优势,与基于光子的治疗相比,在低剂量至中等剂量的照射下,可以使更多的正常肝脏组织免受辐射,同时仍向肿瘤提供高剂量的放射治疗。 PBT疗法在具有大而肿大的肿瘤和/或血管侵犯并伴有周围灌注异常的高风险HCC肝硬化患者中可能特别有益。我们提出了一例62岁男性,患有无法切除的13厘米弥漫性浸润性肝癌,其主要门静脉侵犯和37,200的升高的α-胎蛋白(AFP)不耐受标准索拉非尼治疗。使用同时集成的增强强度调制质子治疗(SIB-IMPT),屏气技术和功能imaging 99m [ 99m Tc]硫胶体单光子发射计算机断层扫描(SPECT / CT),以帮助区分肿瘤和正常肝脏。在治疗后七个月,他通过AFP正常化具有完全的放射学和生化反应,没有放射肝毒性的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号